Developments Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a... February 10, 2025